Share Price, page-9610

It is annoying when that happens, although a few % difference in the long run won't matter too much. The risk reward is very good at this stage (IMO), and I can see the SP moving quickly up when it decides to. We've seen in the last few months that there can be periods where the price and fundamentals are detached but then it correctly corrects itself.

Although PE is a silly metric for a company like this it is funny that Google displays a PE of 15.5 for NEU. It is impacted by the 'one offs' to earnings re: ROW deal in particular. It is interesting in the overall context of other profitable biotech and device companies on the ASX (there aren't many). Companies like CSL and COH persistently trade on elevated valuations for pretty modest forward growth due to the "defensive nature" of their assets. I wonder if or when NEU will get that mark up.